Liebetrau Martin, Burggraf Dorothe, Wunderlich Nathalie, Jäger Gabriele, Linz Wolfgang, Hamann Gerhard F
Department of Neurology, Dr. Horst Schmidt Kliniken, Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany.
Neurosci Lett. 2005 Mar 16;376(3):205-9. doi: 10.1016/j.neulet.2004.11.061. Epub 2004 Dec 31.
The spontaneously hypertensive stroke-prone rat (SHR-SP) is an experimental model of malignant hypertension which lead to secondary alterations of the extracellular matrix. Our aim was to determine ACE-inhibitor related changes of proteases involved in the reconstruction of the extracellular matrix in the brain. Twelve SHR-SP rats were randomized into two groups. Each group was treated with either an antihypertensive dose of ramipril or placebo for 6 months. Brain tissue plasminogen activator (t-PA) and urokinase (u-PA) were quantified by using casein-dependent plasminogen zymography, matrix metalloproteinase (MMP)-2 and MMP-9, by MMP-zymography, and tissue inhibitor of MMP (TIMP)-1 and -2, by reverse zymography. The amounts of u-PA, t-PA, and MMPs were significantly reduced in animals treated with ACE inhibitor. Plasminogen zymography showed a 39% reduction of u-PA in the basal ganglia (p < 0.0001); t-PA expression was reduced by 26% in the cortex and by 33% in the basal ganglia (p < 0.0001). MMP-2 expression was reduced by 15% in the cortex (p < 0.05) and by 10% in the basal ganglia (p < 0.05); MMP-9 expression significantly decreased by 37% in the cortex and by 25% in the basal ganglia (p < 0.0001 each). No differences were observed in the amount of TIMP-1 or TIMP-2. These findings provide new insights into the biochemical mechanisms underlying extracellular matrix proliferation and its modulation by ACE inhibitors. Therapeutic alterations that influence the proteolytic systems might prove important in the prevention of extracellular matrix accumulation and secondary microvascular vessel wall changes.
自发性高血压易中风大鼠(SHR-SP)是一种恶性高血压的实验模型,可导致细胞外基质的继发性改变。我们的目的是确定血管紧张素转换酶(ACE)抑制剂对参与脑内细胞外基质重建的蛋白酶的相关影响。将12只SHR-SP大鼠随机分为两组。每组分别用降压剂量的雷米普利或安慰剂治疗6个月。通过酪蛋白依赖性纤溶酶原酶谱法对脑组织纤溶酶原激活物(t-PA)和尿激酶(u-PA)进行定量,通过MMP酶谱法对基质金属蛋白酶(MMP)-2和MMP-9进行定量,通过反向酶谱法对MMP组织抑制剂(TIMP)-1和-2进行定量。接受ACE抑制剂治疗的动物中,u-PA、t-PA和MMP的含量显著降低。纤溶酶原酶谱显示基底节区u-PA降低39%(p<0.0001);皮质中t-PA表达降低26%,基底节区降低33%(p<0.0001)。皮质中MMP-2表达降低15%(p<0.05),基底节区降低10%(p<0.05);皮质中MMP-9表达显著降低37%,基底节区降低25%(均为p<0.0001)。未观察到TIMP-1或TIMP-2含量的差异。这些发现为细胞外基质增殖及其受ACE抑制剂调节的生化机制提供了新的见解。影响蛋白水解系统的治疗性改变可能对预防细胞外基质积聚和继发性微血管壁变化具有重要意义。